467 citations
,
October 2014 in “European Journal of Endocrinology” This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.
40 citations
,
November 2013 in “European journal of endocrinology” This paper reviews the treatment options for hirsutism and emphasizes the importance of diagnosing its underlying cause and considering patient perception and specific phenotypes, reporting no new clinical results.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
378 citations
,
November 2011 in “Human reproduction update” This review discusses the epidemiology, causes, diagnosis, and management of hirsutism in women, noting that effective treatment requires addressing the root cause as well as the hair growth.
1540 citations
,
October 2008 in “Fertility and Sterility” This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.
502 citations
,
February 2008 in “The Journal of Clinical Endocrinology & Metabolism” This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.
150 citations
,
February 2008 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.
31 citations
,
January 2008 in “Gynecological endocrinology” In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.
75 citations
,
November 2007 in “Clinical endocrinology” This study found that several drugs, including flutamide and spironolactone, significantly reduced hirsutism in women, with reduced effectiveness in those with higher BMI.
352 citations
,
January 2006 in “The Journal of Clinical Endocrinology and Metabolism” This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.
42 citations
,
October 2004 in “Experimental and Clinical Endocrinology & Diabetes” In this study, PCOS was the most common cause of hirsutism among Turkish women, but about 17% had idiopathic hyperandrogenemia with no clear cause identified.
947 citations
,
February 2004 in “The Journal of Clinical Endocrinology and Metabolism” In this study, polycystic ovary syndrome was the most prevalent cause of androgen excess, and suppressive hormonal therapy improved hirsutism, menstrual dysfunction, and acne in most patients, though side effects were common.
289 citations
,
May 2003 in “Journal of Investigative Dermatology” This study demonstrates that human skin is capable of steroid hormone synthesis, but its role in androgenic skin disorders like acne and alopecia is yet to be clarified.
